NCT04090268 2024-01-02
SportTherapy
University of Milano Bicocca
Phase NA Unknown
Clinical Trials
23 trialsNCT05350826 2023-09-21
THEMIS
University Hospital, Toulouse
Phase NA Unknown
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05099068 2022-07-05
PLANET
Centre Leon Berard
Phase NA Unknown
NCT03564470 2022-07-01
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04747093 2021-02-10
Induced-T Cell Like NK Cells for B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 1/2 Unknown
NCT03294980 2021-01-28
OFICE
University Hospital, Brest
Unknown
NCT04516551 2020-11-17
Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT
Xinqiao Hospital of Chongqing
Phase 1 Unknown
NCT03302403 2020-10-08
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
First Affiliated Hospital of Wenzhou Medical University
Phase NA Unknown
NCT04016129 2019-09-19
CAR-T Immunotherapy Targeting CD19- ALL
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03599375 2019-02-26
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
The First Hospital of Jilin University
Phase 1 Unknown
NCT03576807 2018-07-03
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
Phase 1 Unknown
NCT03564977 2018-07-02
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
Qingdao Central Hospital
Phase NA Unknown
NCT01862445 2018-03-22
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT03463928 2018-03-13
A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
Chinese PLA General Hospital
Phase 1 Unknown
NCT03417414 2018-02-07
Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?
Ottawa Hospital Research Institute
Unknown
NCT03398967 2018-01-16
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03166878 2017-06-23
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02968472 2016-11-18
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
The First People's Hospital of Yunnan
Phase 1 Unknown
NCT02813837 2016-06-28
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
Innovative Cellular Therapeutics Co., Ltd.
Phase NA Unknown
NCT02267590 2014-10-17
CLARITY
Royal Marsden NHS Foundation Trust
Unknown
NCT01678430 2012-10-15
RIAltO
University of Liverpool
Phase 3 Unknown